Author + information
- Received October 26, 2009
- Revision received December 1, 2009
- Accepted December 7, 2009
- Published online June 8, 2010.
- Nynke Hofman, MSc*,
- Hanno L. Tan, MD, PhD†,
- Marielle Alders, PhD*,
- Irene M. van Langen, MD, PhD* and
- Arthur A.M. Wilde, MD, PhD†,* ()
- ↵*Reprint request and correspondence:
Dr. Arthur A. M. Wilde, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
Objectives The purpose of this study was to investigate the follow-up and treatment of the mutation-carrying relatives of a proband with an inherited arrhythmia syndrome.
Background The congenital long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and Brugada syndrome (BrS) are primary inherited arrhythmia syndromes that may cause syncope and sudden cardiac death in young individuals. After establishing the disease-causing deoxyribonucleic acid (DNA) mutation in probands, we actively conducted cascade screening to identify, most often asymptomatic, relatives who are also at risk of life-threatening arrhythmias.
Methods We retrospectively collected data from our cardiogenetics database and patient records and analyzed whether the identified carriers received prophylactic treatment.
Results From 1996 to 2008, 130 probands with a disease-causing mutation in one of the involved genes were identified, and 509 relatives tested positive for the disease-causing familial mutation. These subjects subsequently underwent cardiologic investigation (electrocardiography, exercise testing, Holter monitoring, ajmaline testing, echocardiography, where appropriate). After a mean follow-up of 69 ± 31 months (LQTS), 60 ± 19 months (CPVT), and 56 ± 21 months (BrS), treatment was initiated and ongoing in 65% (199 of 308), 71% (85 of 120), and 6% (5 of 81) of the relatives in the LQTS, CPVT, and BrS families, respectively. Eight carriers were lost to follow-up. Treatment included drug treatment (n = 249) or implantation of pacemakers (n = 26) or cardioverter-defibrillators (n = 14). All mutation carriers received lifestyle instructions and a list of drugs to be avoided.
Conclusions Cascade screening in families with LQTS, BrS, or CPVT, which was based on DNA mutation carrying and subsequent cardiologic investigation, resulted in immediate prophylactic treatment in a substantial proportion of carriers, although these proportions varied significantly between the different diseases.
Dr. Tan was supported by the Netherlands Organization for Scientific Research(NWO, ZonMW-Vici 918.86.616). Dr. Wilde's research program is supported by ICIN project 27 and a Leducq programgrant CVD05“Alliance Against Sudden Cardiac Death.”
- Received October 26, 2009.
- Revision received December 1, 2009.
- Accepted December 7, 2009.
- American College of Cardiology Foundation